1 / 8

2015-2019 Global Type 2 Diabetes Therapeutics Market

Type 2 diabetes is a chronic condition, which arises due to either the inability of the body to produce enough insulin or insulin resistance, or both. Insulin is a peptide hormone produced by the Islets of Langerhans (pancreatic cells). It is produced in an immature form called preproinsulin, which is proteolytically cleaved to obtain proinsulin and then insulin. Type 2 diabetes nearly accounts for 90-95 percent of the total diabetic cases. Type 2 diabetes is usually diagnosed in middle-aged and older people; however, it can occur even during childhood. Type 2 diabetes was also known as adult-onset diabetes or non-insulin-dependent diabetes. Risk factors for type 2 diabetes include high blood pressure, advancing age, overweight, history of gestational diabetes, family history of diabetes, ethnicity, poor nutrition during pregnancy, unhealthy diet, physical inactivity, and IGT. The Global Type 2 Diabetes Therapeutics market to grow at a CAGR of 7.15 percent over the period 2014-2019. Read more details at: http://www.bigmarketresearch.com/global-type-2-diabetes-therapeutics-2015-2019-market

janiebmr
Download Presentation

2015-2019 Global Type 2 Diabetes Therapeutics Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Global Type 2 Diabetes Therapeutics Market 2015-2019

  2. DESCRIPTION About Type 2 Diabetes Type 2 diabetes is a chronic condition, which arises due to either the inability of the body to produce enough insulin or insulin resistance, or both. Insulin is a peptide hormone produced by the Islets of Langerhans (pancreatic cells). It is produced in an immature form called preproinsulin, which is proteolytically cleaved to obtain proinsulin and then insulin. Type 2 diabetes nearly accounts for 90-95 percent of the total diabetic cases. Type 2 diabetes is usually diagnosed in middle-aged and older people; however, it can occur even during childhood. Type 2 diabetes was also known as adult-onset diabetes or non-insulin-dependent diabetes. Risk factors for type 2 diabetes include high blood pressure, advancing age, overweight, history of gestational diabetes, family history of diabetes, ethnicity, poor nutrition during pregnancy, unhealthy diet, physical inactivity, and IGT. The Global Type 2 Diabetes Therapeutics market to grow at a CAGR of 7.15 percent over the period 2014-2019. Read more details at:http://www.bigmarketresearch.com/global-type-2-diabetes-therapeutics-2015-2019-market

  3. REPORT OVERVIEW Covered in this Report This report covers the present scenario and the growth prospects of the Global Type 2 Diabetes Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of following drugs: • DPP-4 inhibitors • Biguanides • Insulins • GLP-1 receptor agonists • Thiazolidenediones • Sulfonulureas • SGLT-2 inhibitors • a-Glucosidase inhibitors • Others (amylinomimetics, bile acid sequestrants, and dopamine receptor agonists)

  4. REPORT OVERVIEW Further, the territories considered in the report include: • Americas (US, Brazil, and Mexico) • 5EU (France, Germany, Italy, Spain, and UK) • APAC (China, Japan, India, Russia, and other APAC countries) Global Type 2 Diabetes Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Type 2 Diabetes Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

  5. KEY REGIONS Key Regions • Americas • APAC • EMEA Key Vendors • AstraZeneca • Novartis • Novo Nordisk Other Prominent Vendors • BoehringerIngelheim • Bristol-Myers Squibb • Eli Lilly • Merck • Sanofi

  6. KEY AUDIENCES Market Driver • Increased Awareness on Type 2 Diabetes • For a full, detailed list, view our report Market Challenge • Poor Diagnosis Rate • For a full, detailed list, view our report Market Trend • Focus on Emerging Markets • For a full, detailed list, view our report

  7. KEY AUDIENCES Key Questions Answered in this Report • What will the market size be in 2019 and what will the growth rate be? • What are the key market trends? • What is driving this market? • What are the challenges to market growth? • Who are the key vendors in this market space? • What are the market opportunities and threats faced by the key vendors? • What are the strengths and weaknesses of the key vendors? Enquire about report:http://www.bigmarketresearch.com/report-enquiry/169950

  8. Get Full Information At: http://www.bigmarketresearch.com/global-type-2-diabetes-therapeutics-2015-2019-market

More Related